Provenge News

erisian Member Posts: 107
edited March 2014 in Prostate Cancer #1

Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented

"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."

Let's hope so.


  • erisian
    erisian Member Posts: 107
    More info
    "...PROVENGE increased three-year survival by 40 percent compared to placebo (32.1 percent vs 23.0 percent), the median survival difference of PROVENGE compared to placebo was maintained at 4.1 months, with a 24.1 percent reduction in the risk of death..."

    Here are a couple of links on the subject:

    Dendreon press release:

    PDF of presentation on the IMPACT study given at ASCO-GU conference: